Strategic partnerships EyeGate has established exclusive global licensing agreements with Valeant for the EGP-437 product, indicating a proven path for channel expansion and co-commercialization. Sales opportunities could focus on leveraging Valeant’s distribution and ophthalmology reach to accelerate market access in existing and new regions.

Ocular delivery royalty The EyeGate II Delivery System for EGP-437 demonstrates a differentiated, device-enabled topical corticosteroid delivery approach. Opportunities exist to cross-sell or out-license complementary delivery platforms or to partner with clinics seeking innovative, efficient postoperative inflammation management.

Clinical progress With OBG advancing as a wound healing and lubrication solution post-PRK and EGP-437 in multiple inflammatory indications, there is potential to target ophthalmic surgeons and centers performing refractive surgery, cataract procedures, and uveitis management for adoption of EyeGate therapies.

Financial footing Current revenue is under one million with strategic financing history and a sizeable cash-use runway implied by ongoing trials and partnerships. This signals openness to collaboration, co-development deals, and milestone-based partnerships that reduce upfront risk for potential customers and investors.

Leadership and timing Recent executive hires and promotions in finance and leadership suggest a focus on governance, scalability, and commercialization readiness. This creates a favorable window for engaging business development discussions around accelerating product rollout, manufacturing partnerships, and small-to-mid scale launches.